Overview

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Status:
Completed
Trial end date:
2016-06-22
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics
Treatments:
Brexanolone